Analytical Data
-
Gene name
ABL1
- Application
-
Alternative Names
Abelson murine leukemia viral oncogene homolog 1Abelson tyrosine-protein kinase 1;Proto-oncogene c-Ablp150
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00519
-
Expression Region
4-194aa
-
Molecular Weight
48.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABL1, or Abelson murine leukemia virus gene 1, is a crucial proto-oncogene that encodes a non-receptor tyrosine kinase, playing a significant role in various cellular processes, including cell division, differentiation, and apoptosis. Its dysregulation is prominently associated with several types of cancers, particularly chronic myeloid leukemia (CML), where the BCR-ABL fusion protein acts as a constitutively active tyrosine kinase, driving malignant transformation. The development of BCR-ABL-targeted therapies, notably Imatinib (Gleevec), revolutionized CML treatment and highlighted the importance of ABL1 in cancer biology. Researchers have been focused on producing recombinant ABL1 proteins to better understand its biochemical properties, signaling pathways, and interactions with other molecules. This research aids in deciphering the mechanisms of BCR-ABL-associated oncogenesis and helps in identifying potential therapeutic targets. Additionally, the generation of ABL1 protein variants and their recombinant forms offers insights into drug resistance mechanisms and the development of second-generation tyrosine kinase inhibitors. As studies continue to explore the nuances of ABL1’s role in cancer, the insights gained from recombinant ABL1 protein research are crucial for advancing personalized medicine strategies and improving therapeutic outcomes for patients with ABL1-related malignancies.
